Centogene N.V. Races Against Nasdaq Delisting
Company Announcements

Centogene N.V. Races Against Nasdaq Delisting

Centogene NV (CNTG) has released an update.

Centogene N.V., a biotech company, has been granted an extension until August 26, 2024, to meet Nasdaq’s minimum Market Value of Publicly Held Shares requirement and avoid delisting. The company is actively working on a strategic review process, which includes a potential sale, to comply with the listing standards. However, the possibility of achieving these milestones and maintaining its Nasdaq listing remains uncertain.

For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCentogene and C-Path Strengthen Drug Development Alliance
TheFlyCentogene & C-Path team on LD research and drug development
GlobeNewswireC-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!